<ul><li>Piramal Pharma reported a net profit increase of 51.6% to Rs 153 crore in the Q4, compared to Rs 101 crore in the same quarter last year.</li><li>Goldman Sachs expressed confidence in Piramal Pharma's potential for top-quartile profit growth, driven by high operating and financial leverage.</li><li>Despite revenue and Ebitda growth below Goldman Sachs' estimates, profit before tax for Piramal Pharma was largely in line.</li><li>The brokerage firm has initiated coverage on Piramal with a buy rating, expecting significant profit growth and setting a target price of Rs 265 per share with a 21% upside potential.</li></ul>

Piramal Pharma Q4 Results Review: Goldman Sachs Highlights Strong Profit Growth Potential

Discover more